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Background: Lamivudine (LAM) is associated with the highest known rate of resistance mutations among
nucleotide analogs used to treat chronic hepatitis B virus (HBV) infection. Despite this, LAM continues in widespread
use, especially in combination therapies. The primary LAM resistance mutation (rtM204V/I) occurs in the YMDD
motif of HBV polymerase. The aim of this study was to characterize Brazilian HBV isolates from acute and chronic
cases by direct sequencing, and to identify HBV quasispecies in the YMDD motif using a pyrosequencing method
capable of detecting single-nucleotide polymorphisms. HBV DNA from serum samples of 20 individuals with acute
HBV infection and 44 with chronic infection undergoing antiviral therapies containing LAM were analyzed by direct
sequencing and pyrosequencing methods.
Results: Phylogenic analyses of direct-sequenced isolates showed the expected genotypes (A, D and F) for the
Brazilian population in both acute and chronic infections. However, within genotype A isolates, subgenotype A2
was more frequently detected in acute cases than in chronic cases (P = 0.012). As expected, none of the individuals
with acute hepatitis B had LAM-resistant isolates as a dominant virus population, whether detected by direct
sequencing or pyrosequencing. However, pyrosequencing analyses showed that 45% of isolates (9/20) had minor
subpopulations (4-17%) of LAM-resistant isolates. Among chronic patients undergoing LAM treatment, YMDD
mutants were frequently found as a dominant virus population. In cases where wild-type virus was the dominant
population, subpopulations of YMDD variants were usually found, demonstrating the complexity of HBV
quasispecies.
Conclusions: YMDD variants were frequently detected as a minor population in acute HBV infection. The
occurrence of pre-existing variants may lead to a high frequency of resistant mutants during antiviral therapy in the
chronic phase. In chronic infection, detection of YMDD variants before virological or biochemical breakthrough
might contribute to making better therapy choices and thus improving treatment outcome.Background
The genetic variability of hepatitis B virus (HBV) contri-
butes to the development of drug resistance, the major
drawback of currently used antiviral treatments for chronic
hepatitis B. Nucleoside/nucleotide analogs (NAs) are orally
administered drugs designed to inhibit the function of HBV
reverse transcriptase (rt). Although these drugs are highly
effective in controlling viral replication, their efficacy is
often hindered by the selection of drug-resistant viruses [1].* Correspondence: selma@ioc.fiocruz.br
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reproduction in any medium, provided the orThe selection pressure imposed by the presence of the drug
gradually favors an increase in the population of viruses
with mutations that confer resistance to the drug; this is
often followed by an increase in viral load and serum
alanine aminotransferase levels, and progression of liver
disease [2,3]. Lamivudine (LAM), the first NA drug licensed
for the treatment of chronic hepatitis B, is currently still in
widespread use. This continuing use is in addition to more
recently developed drugs that are efficient in the rescue
therapy of LAM-resistant mutant [4]. LAM use is asso-
ciated with the highest rate of resistance among NA drugs;
this resistance progressively increases over the course of
treatment, ultimately affecting 80% of patients after 48td. This is an Open Access article distributed under the terms of the Creative
commons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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HBV rt protein that is associated with LAM resistance is
residue 204 in the highly conserved tyrosine-methionine-
aspartate-aspartate (YMDD) motif of the nucleotide-
binding site; in general, the methionine in this sequence is
replaced by either valine or isoleucine (rtM204V/I) [8,9].
This primary LAM-resistant mutant, rtM204V/I, affects
viral replication fitness. Compensatory mutations in the rt
domain (rtL180M, rtV173L, rtL80I/V) that partially restore
replication efficiency are often co-selected in HBV rt204
mutants [1]. To date, the most commonly used method for
detecting drug resistance mutations is by direct sequen-
cing after polymerase chain reaction (PCR) amplification.
In addition to being a laborious and time-consuming
method, direct PCR sequencing is limited by its inability
to detect variants that are poorly represented in the hete-
rogeneous virus population present in a patient’s circula-
tion. Therefore, other molecular techniques, including
restriction fragment length polymorphism (RFLP) analysis
[10-12], 5’-nuclease assays [10], melting point analysis
[13], hybridization-based genotyping methods (e.g., mass
spectrometry) [14], line-probe assays [15], DNA chip tech-
nology [16] and real-time PCR using mutation-specific
primers [17], have been used to discriminate population
mixtures [18,19].
Pyrosequencing is a new sequencing method that detects
DNA polymerase activity by measuring the pyrophosphate
(PPi) released by the addition of a dNMP to the 3’ end of a
primer. It allows determination of the sequence of a single
DNA strand by synthesizing a complementary strand, one
base pair at a time, and detecting which base is added at
each step. Pyrosequencing is currently the fastest, and
probably most sensitive, method available for detecting
small subpopulations of resistant virus and the unique
capable of presents quantitative sequence data [7,19,20].
Here, HBV isolates from Brazilian patients with acute and
chronic infections undergoing antiviral therapies containing
LAM were genotyped and characterized by direct sequen-
cing. Single-nucleotide polymorphisms (SNPs) in the
YMDD motif of these HBV isolates were analyzed and
quantified using a pyrosequencing method capable of rap-
idly sequencing short DNA sequences. Pyrosequencing




In a parallel study [21], 129 samples from chronically
HBV-infected patients undergoing interferon or NA analog
therapy were examined for drug-resistance mutations. In
the present study, serum samples from 44 of these patients
undergoing LAM therapy as a first-line treatment were
analyzed. These samples were referred to the public central
Noel Nutels laboratory in Rio de Janeiro, Brazil, for theassessment of HBV loads. Individuals with clinical symp-
toms of acute hepatitis were monitored in the Viral
Hepatitis Ambulatory Center of our Institution. The diag-
nosis of acute HBV infection was confirmed by positivity
to anti-HBc IgM antibodies (AxSYM CORE-M; Abbott,
Delkenheim, Germany). Twenty samples from these indi-
viduals were included in the present study. The research
use of these samples was approved by the Fiocruz Ethics
Committee, and written informed consent was obtained
from all subjects.
HBV direct sequencing and HBV quantification by real-
time PCR
HBV DNA was extracted from serum samples using the
High Pure Viral Nucleic Acid kit (Roche Applied Science,
Mannheim, Germany) according to the manufacturer’s
instructions. Viral DNA was eluted in 50 μL of Elution
Buffer.
For the direct Sanger sequencing method, the pre-S/S
genome region was amplified by semi-nested PCR. The
first-round PCR product was amplified with the primer
pair PS1 and P3, and the second round was performed
using the sense primer PS1 and a mixture of two anti-
sense primers, S2 and S22, as previously described [22].
DNA was amplified using 5 U/μL Taq DNA polymerase
(Invitrogen, San Diego, CA, USA) and 10 mM dNTPs in
a final volume of 50 μL. First round PCR was performed
using the following conditions: 94°C for 3 min (initial
denaturation), then 30 cycles of 94°C for 30 s, 55°C for 30
s and 72°C for 1 min 30 s, followed by a final elongation
step (7 min at 72°C). Second-round thermocycling condi-
tions were 94°C for 3 min, then 30 cycles of 95°C for 30 s,
52°C for 10 s and 72°C for 2 min, followed by a final
elongation step (7 min at 72°C). The lower limit of detec-
tion of the PCR assay was 100 copies/mL. PCR products
were purified using the Wizard SV Gel and PCR Clean-Up
System (Promega, Madison, USA), and were prepared for
sequencing using a Big Dye Terminator 3.1 Cycle Sequen-
cing Kit (Applied Biosystems, Foster City, CA, USA) with
external primers PS1 and S2 or S22, internal sense primer
S4 (5'-TGCTGCTATGCCTCATCTTCT-3'; nucleotides
[nt] 416-436) and antisense primer S7 (5'-TGAGCCAG
GAGAAACGGGCT-3'; nt 676-656). The sequence was
determined by separation and analysis of extension pro-
ducts using an automated ABI 3730 DNA Analyzer (Ap-
plied Biosystems). HBV genotyping was performed by
phylogenetic analysis of the pre-S/S gene of the sequences
determined in this study in the context of HBV sequences
representing all known genotypes available in GenBank.
Sequences were aligned using the ClustalW program [23],
and the phylogenetic tree was generated using the
neighbor-joining method (bootstrap resampling test with
1,000 replicates) in MEGA version 4.0 software [24].
Drug-resistance mutations were analyzed based on the
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open reading frame that overlaps the pre-S/S gene
covering the rt domain from amino acid 1 to 230. Samples
positive for HBV DNA were quantified by TaqMan real-
time PCR technology, as previously described [25], using
the probe, 5’-FAM-TGTTGACAARAATCCTCACAA
TACCRCAGA-TAMRA-3´ (nt 218-247). The assay has a
limit of detection of 10 copies/reaction (i.e., 100 copies/mL
serum).
Categorical variables were compared using Fisher’s
exact tests, and differences between continuous variables
were assessed using Student’s t-tests. Differences were
considered statistically significant for P-values< 0.05.
Statistical analyses were performed using SPSS version
17 (SPSS, Chicago, IL, USA).
Primer design and PCR assays for pyrosequencing
Pyrosequencing was performed using PyroMark Q96 ID
(QIAGEN Valencia, CA, USA). This instrument offers
quantitative SNPs and mutation analysis by rapidly sequen-
cing short stretches of DNA directly from PCR templates.
PCR amplification and pyrosequencing primers were
designed using PyroMark Assay Design 2.0 software. The
following primers were designed to amplify a 218-bp
fragment of the HBV rt polymerase domain containing the
YMDD motif: forward primer, 5’-TTGCACCTGTATTCC
CAT-3’ (nt 594-611); reverse primer, 5’-AAAATTGGTAA
CAGCGGTAWA AA-3’ (nt 791-812). The forward primer
was 5’ biotin-labeled to enable preparation of a single-
stranded template for pyrosequencing. The sequencing
primer (5’-GTTTGGCTT TCAGYTAT-3’; nt 724-736) was
located immediately upstream of codon rt204. DNA was
amplified using 5 U/μL Platinum Taq DNA polymerase
High Fidelity (Invitrogen), 10 mM dNTPs, 10X PCR buffer,
50 mM MgCl2 and 10 μM primer mix in a final volume of
50 μL under the following thermocycling conditions: initial
denaturation at 94°C for 3 min, then 30 cycles of 94°C for
30 s, 55°C for 30 s and 68°C for 30 s, followed by a final
elongation step (5 min at 68°C).
Biotinylated PCR products were hybridized to strepta-
vidin-coated beads and purified using the PyroMark Q96
Vacuum Prep Workstation (Qiagen, Valencia, CA, USA)
according to the manufacturer’s instructions. Sequencing
primers were annealed by incubating at 80°C for 2 min.
Pyrosequencing reactions were performed using the
PyroMark Gold Q96 SQA Reagents in the PyroMark
Q96 ID (QIAGEN). The dispensation order algorithm
for pyrosequencing was CAGTACGCATG. Data collec-
tion and quantification analyses were performed using
PyroMark ID software. Mixtures of plasmids carrying
wild-type (WT) and YVDD-resistant (MUT) sequences
were prepared to evaluate the ability of the pyrosequen-
cing method to accurately detect and quantify minor
sequence variants. Mixtures ranging from 100% WT-0%MUT to 0% WT-100% MUT were prepared at incre-
ments of 10% of each plasmid. A mixture of 95%-5% of
each plasmid was tested to assess the sensitivity of the
pyrosequencing assay in detecting minor subpopulations
as low as 5% of the total.
Results and discussion
Genotyping and subgenotyping of circulating HBV isolates
in the samples analyzed (Table 1) showed no significant
differences in genotype distributions among acute and
chronic infections under LAM selective pressure. In acute
infection, 16 of 20 HBV isolates (80%) under study
belonged to genotype A, three (15%) were from genotype
D, and the remaining one (5%) belonged to genotype F. In
samples from chronic cases, the following genotype
distribution was found: 25/44 (56.8%) genotype A, 13/44
(29.5%) genotype D, 5/44 (11.4%) genotype F, and one
(2.3%) genotype B. Among isolates from genotype A,
subgenotypes A1 and A2 were found. The ratio of subgeno-
types A1/A2 in acute cases (8/8, 50% each) was significantly
different from that in chronic cases (22/3, 88% A1 and
12% A2; P= 0.012). If the equal distribution of subgeno-
types A1 and A2 among newly infected individuals (acute
infection) reflects an increase in subgenotype A2 in Brazil,
this suggests that the profile of circulating subgenotypes in
Brazil could be changing. Alternatively, differences between
the two subgenotypes could be related to disease progres-
sion (resolution of acute infection or progression to chroni-
city). These possibilities warrant further investigation.
Surprisingly, acute HBV patients had relatively low HBV
titers compared to what would have been expected for an
acute HBV infection, ranging from 6.2 x 102 to 1.4 x 106
copies/mL (mean viral load, 2.0 x 105 copies/mL; median
viral load, 2.0 x 104 copies/mL). Chronic patients had
HBV titers ranging from 9.4 x 102 to 2.4 x 109 copies/mL.
The mean viral load was 1.4 x 105 copies/mL, and the
median was 5.6 x 104 copies/mL.
The direct PCR Sanger sequencing method (population-
based sequencing approach) detected only the major
population in our assays. Literature reports indicate that
only minor populations present as more than 20% of the
total quasispecies pool can be detected by the Sanger
method [26]. To test the ability of pyrosequencing to detect
minor sequence variants of the YMDD population, we
evaluated different proportions of plasmids containing WT
(rtM204) and MUT (rtV204) sequences. Allelic quantifica-
tion based on pyrograms indicated accurate detection when
minor variants represented at least 5% of the total circula-
ting population (Figure 1). A value of 4% was subsequently
used as the lower limit of detection of minor populations
by pyrosequencing under our experimental conditions.
Other methods capable of detecting (but not capable of
quantifying) viral mutants that constitute as little as 4-5%
of the total population, such as RFLP analyses and line-
Table 1 Comparisons of YMDD variants in serum of patients with acute and chronic HBV infection detected by direct sequencing and pyrosequencing
Patient number Type of infection Treatment Duration (months) Viral load (cp/mL) Sub genotype Direct sequencing Pyrosequencing % amino acid
WT MUT M V I
ATG Codon ATG (codon) (codon)/(codon)
1969 acute - - 1.1x106 A1 M/ATG - 100 - -
2098 acute - - 1.4x106 A1 M/ATG - 100 - -
1377 acute - - 3.5x104 A1 M/ATG - 100 - -
1504 acute - - 6.2x102 A1 M/ATG - 100 - -
1379 acute - - 2.8x104 A1 M/ATG - 95 - 5 (ATT)
1419 acute - - 6.5x103 A1 M/ATG - 100 - -
1781 acute - - 6.6x102 A1 M/ATG - 95 - 5 (ATT)
1510 acute - - 8.6x103 A1 M/ATG - 83 - 17 (ATA)
1384 acute - - 3.3x105 A2 M/ATG - 100 - -
2190 acute - - - A2 M/ATG - 94 6 (GTT) -
603 acute - - 1.2x105 A2 M/ATG - 100 - -
1472 acute - - 3.0x103 A2 M/ATG - 100 - -
1386 acute - - 1.3x105 A2 M/ATG - 96 - 4 (ATT)
1120 acute - - 7.1x102 A2 M/ATG - 93 - 7 (ATT)
1393 acute - - 7.2x103 A2 M/ATG - 100 - -
1889 acute - - 5.6x105 A2 M/ATG - 96 - 4 (ATT)
1474 acute - - 5x104 D2 M/ATG - 100 - -
1980 acute - - 2.5x103 D2 M/ATG - 94 6 (GTT) -
1314 acute - - 2.0x104 D3 M/ATG - 100 - -
1570 acute - - 1.3x103 F2 M/ATG - 94 - 6 (ATT)
NN003 chronic LAM 01 3.7x104 A1 M/ATG 94 - 6 (ATT)
NN004 chronic LAM 06 1.7 x104 A1 M/ATG 96 - 4 (ATT)
NN124 chronic LAM 06 9.7 x102 A1 - V/GTG - 40 (GTG) 60 (ATT)
NN092 chronic LAM 07 7.6 x106 A1 M/ATG - 100 - -
NN006 chronic LAM+ TDF 12 1.7 x104 A1 - V/GTG - 100 (GTG) -
NN026 chronic LAM 12 1.2 x107 A1 - V/GTG - 100 (GTG) -
NN041 chronic LAM 12 1.3 x104 A1 M/ATG - 94 - 6 (ATT)
NN043 chronic LAM 12 4.2 x105 A1 M/ATG - 100 - -
NN132 chronic LAM 12 9.4 x102 A1 - V/GTG 10 75 (GTG) 15 (ATT)
NN123 chronic LAM 18 2.4 x109 A1 M/ATG - 94 - 6 (ATA)



















Table 1 Comparisons of YMDD variants in serum of patients with acute and chronic HBV infection detected by direct sequencing and pyrosequencing
(Continued)
NN024 chronic LAM 24 5.2 x107 A1 - V/GTG - 100 (GTG) -
NN010 chronic LAM 36 4.9 x105 A1 - I/ATT 3 - 93 (ATT)/4 (ATA)
NN018 chronic LAM 36 4.6 x103 A1 - V/GTG 6 94 (GTG) -
NN019 chronic LAM 36 3.0 x103 A1 M/ATG - 96 - 4 (ATA)
NN027 chronic LAM 36 2.8 x104 A1 M/ATG - 95 - 5 (ATT)
NN037 chronic LAM 36 4.8 x105 A1 M/ATG - 100 - -
NN079 chronic LAM 36 9.6 x103 A1 M/ATG - 100 - -
NN087 chronic LAM 72 1.1 x104 A1 M/ATG - 100 - -
NN007 chronic LAM 84 2.8 x104 A1 - V/GTG - 100 (GTG) -
NN028 chronic LAM 108 1.8 x109 A1 V/GTG - 100 (GTG) -
NN032 chronic LAM+ TDF 132 1.2 x104 A1 - V/GTG - 100 (GTG) -
NN025 chronic LAM 05 4.3 x104 A2 M/ATG - 100 - -
NN014 chronic LAM 07 1.4 x105 A2 - I/ATT - - 100 (ATT)
NN042 chronic LAM 12 5.4 x107 A2 - V/GTG 6 94 (GTG) -
NN022 chronic LAM+ADV 24 1.7 x105 B - I/ATT - 25 (GTG) 70 (ATT)
NN074 chronic LAM 06 6.5 x105 D2 - V/GTG - 100 (GTG) -
NN125 chronic LAM+ TDF 12 2.5 x103 D2 - I/ATT - - 100 (ATT)
NN001 chronic LAM 60 2.4x104 D3 - V/GTG - 100 (GTG) -
NN091 chronic LAM 06 4.3 x103 D3 - I/ATT - - 100 (ATT)
NN096 chronic LAM 06 3.1 x103 D3 M/ATG - 100 - -
NN097 chronic LAM 06 5.3 x106 D3 M/ATG - 95 - 5 (ATT)
NN129 chronic LAM 06 7.2 x108 D3 - V/GTG - 95 (GTG) 5 (ATT)
NN029 chronic LAM 12 7.0 x104 D3 M/ATG - 86 4 (GTG) 6 (ATA)/4 (ATT)
NN038 chronic LAM+ TDF 12 2.9 x105 D3 M/ATG - 100 - -
NN077 chronic LAM 12 9.7 x105 D3 - I/ATT 4 - 96 (ATT)
NN034 chronic LAM+ADV 24 1.0 x105 D3 - V/GTG - 90 (GTG) 10 (ATT)
NN075 chronic LAM 60 3.2 x103 D3 M/ATG - 100 - -
NN031 chronic LAM 72 6.8 x107 D3 - V/GTG - 100 (GTG) -
NN126 chronic LAM 06 1.9 x108 F1b - I/ATC - 30 (GTG) 70 (ATC)
NN105 chronic LAM 06 3.7 x108 F2 - V/GTG - 100 (GTG) -
NN078 chronic LAM 12 1.2 x106 F2 M/ATG - 95 - 5 (ATT)
NN134 chronic LAM 12 2.7 x104 F2 - I/ATT - 25 (GTG) 75 (ATT)
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suitable for high-throughput screening, or are subject to a
greater number of false-positive and false-negative results
than sequencing [7,20]. Our result confirms previous
reports that pyrosequencing is the most sensitive method(A)
(C)
(E)
Figure 1 Pyrosequencing analysis with allelic quantification of A/G fo
mixtures of WT (YMDD) and MUT (YVDD) plasmids. (A) 100% WT-0% M
MUT; (E) 95% WT-5% MUT. The results of quantification of each nucleotideavailable for detecting small subpopulations of resistant
virus and, as such, is likely to become the method of choice
in the near future [7,19,20,27,28].
Comparisons of YMDD variants in serum of patients
with acute and chronic HBV infection detected by direct(B)
(D)
r the first position of codon M/ATG and V/GTG in different
UT; (B) 50% WT-50% MUT; (C) 66% WT33% MUT; (D) 90% WT-10%
are indicated above the pyrograms (as %).
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expected, none of the individuals with acute hepatitis B had
LAM-resistant isolates as a dominant virus population,
whether detected by direct sequencing or pyrosequencing.
However, because of its greater ability to detect viral subpo-
pulations, pyrosequencing revealed that 11/20 (55%) of the
individuals with acute hepatitis B had only WT isolates,
whereas 9/20 (45%) had minor subpopulations of LAM-
resistant isolates varying from 4% to 17%. The detection of
pre-existing resistant variants in acute phase provides infor-
mation helpful in choosing an appropriate antiviral regimen
whether individuals have become chronic carriers, and thus
need to start an antiviral regimen.
Thirty-eight patients (86.4%) with chronic hepatitis B
were undergoing a LAM monotherapy regimen, whereas
the other six (13.6%) were receiving combination therapy of
LAM plus adefovir dipivoxil (ADV) or tenofovir disoproxil
fumarate (TDF). There was no significant association
between the treatment duration and the occurrence of
LAM-resistant isolates. Direct sequencing methods deter-
mined that WT isolates were present in 19 of 44 patients
(43.2%) and LAM-resistant isolates were present in 25 of
44 patients (56.8%), with a predominance of the YVDD
variant (17/25, 68%) compared to the YIDD variant (8/25,
32%). Pyrosequencing confirmed the presence of exclu-
sively WT isolates in 10 of 19 samples (52.6%) character-
ized as WT by direct sequencing. In the other nine
samples (47.4%), pyrosequencing was able to detect the
presence of minor subpopulations of LAM-resistant
isolates. Of 25 samples characterized as LAM-resistant by(A)
Figure 2 Discrepancy between direct sequencing and pyrosequencing
nucleotides (GTG) coding for the rtM204V variant, although the electrophe
corresponding to the first and third nucleotide position of codon ATT (rt20
YVDD (V/GTG) variants.direct sequencing, pyrosequencing confirmed the presence
of only one population of resistant mutants (either YVDD
or YIDD) in 14 (56%). The remaining 11 samples (44%)
contained a mixture of mutant variant populations or a
minor subpopulation composed of WT isolates. Pyrose-
quencing proved to be a powerful tool for detecting co-
circulating strains in a complex population. This allowed
resistant HBV to be detected before any evidence of viro-
logical or biochemical breakthrough, thus increasing the
possibility of a correct choice of rescue therapy and
increasing the likelihood of successful treatment.
Interestingly, all but two individuals whose major virus
population was composed of WT isolates and a small per-
centage of resistant variants detected by pyrosequencing
had a YIDD variant as a minor subpopulation, suggesting
that the rtM204I mutation may naturally occur more often
and replicate more efficiently than YVDD variants in
environments with little or no selection pressures. The only
disagreement between the results of direct sequencing and
pyrosequencing was for sample NN124. The direct sequen-
cing method detected nucleotides (GTG) coding for
rt204V, although the electropherogram indicated mixtures
with small quantities of nucleotides A and T corresponding
to the first and third position, respectively, of codon rt204I
(Figure 2A). In contrast, pyrosequencing indicated a
majority (~60%) of rt204I variant and about 40% rt204V
variant (Figure 2B). The same discrepant results were also
obtained when the segment used as template for the direct
sequencing method was amplified using pyrosequencing







in sample NN124. The direct sequencing method (A) detected the
rogram indicated mixtures with small quantities of nucleotides A and T
4I). Pyrosequencing (B) detected about 60% YIDD (I/ATT) and 40%
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http://www.biomedcentral.com/1471-2180/12/96similar amounts of YIDD and YVDD variants (60% vs.
40%) reported by pyrosequencing.
Conclusions
Pyrosequencing is a rapid, specific, and sensitive tool
that may be useful in detecting and quantifying subpo-
pulations of resistant viruses. Here, YMDD variants were
frequently detected by this method as a minor popula-
tion in acute HBV infection. Co-circulation of mixtures
of WT and mutant isolates of YMDD variants was fre-
quently revealed in treated, chronic hepatitis patients by
pyrosequencing. Detection of YMDD variants before
their detection by conventional sequencing methods
might contribute to making more informed drug choices
and thus improving the outcome of therapy.
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